Alcon Inc.
SWX:ALC Lagerbericht
Marktkapitalisierung: CHF 38.2b
Alcon Zukünftiges Wachstum
Future Kriterienprüfungen 2/6 Alcon wird ein jährliches Gewinn- und Umsatzwachstum von 9.7% bzw. 6.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 9.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 8.5% betragen.
Wichtige Informationen
9.7%
Wachstumsrate der Gewinne
Medical Equipment Gewinnwachstum 13.9% Wachstumsrate der Einnahmen 6.3% Zukünftige Eigenkapitalrendite 8.5% Analystenabdeckung Good
Zuletzt aktualisiert 13 Nov 2024
Jüngste Aktualisierungen zum künftigen Wachstum
Alle Updates anzeigen
Third quarter 2024 earnings: EPS exceeds analyst expectations Nov 13
Alcon Inc. Revises Earnings Guidance for the Year 2024 Nov 13
Subdued Growth No Barrier To Alcon Inc.'s (VTX:ALC) Price Nov 11
Alcon Announces the U.S. Launch of PRECISION®, the Only One-Week Replacement Contact Lens Nov 07
Alcon (VTX:ALC) Might Have The Makings Of A Multi-Bagger Oct 28
Do Alcon's (VTX:ALC) Earnings Warrant Your Attention? Oct 15
CEO & Director notifies of intention to sell stock Sep 15
Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet Sep 04
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 21 Alcon Inc. Maintains Earnings Guidance for the Year 2024
Now 24% undervalued Aug 03
Investor Optimism Abounds Alcon Inc. (VTX:ALC) But Growth Is Lacking Jul 27
A Look At The Fair Value Of Alcon Inc. (VTX:ALC) Jul 13
Alcon's Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance Jun 24
Should You Be Adding Alcon (VTX:ALC) To Your Watchlist Today? Jun 24
Alcon's (VTX:ALC) Returns On Capital Are Heading Higher Jun 10
These 4 Measures Indicate That Alcon (VTX:ALC) Is Using Debt Reasonably Well May 28
First quarter 2024 earnings: EPS exceeds analyst expectations May 14
Upcoming dividend of CHF0.24 per share May 10
Alcon Inc. Approves Gross Dividend May 09
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and Its Hydrus Microstent for Microinvasive Glaucoma Surgery Apr 30
Dividend of CHF0.24 announced Apr 10
Alcon Inc.'s (VTX:ALC) Shareholders Might Be Looking For Exit Apr 03
Alcon Announces Management Changes Mar 27
Here's Why Alcon (VTX:ALC) Has Caught The Eye Of Investors Mar 21
Alcon Inc. Launches Clareon Presbyopia Correcting IOLs in India Mar 12
President of North America notifies of intention to sell stock Mar 03
Results: Alcon Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates Mar 01 Alcon Inc. Proposes Dividend for the Year 2023
Full year 2023 earnings: EPS exceeds analyst expectations Feb 28
Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet Feb 15
Alcon Announces Positive Topline Results from Phase 3 Comet Trials of AR-15512, A Novel Topical Drug Candidate for Dry Eye Jan 10
Alcon Inc.'s (VTX:ALC) Business Is Yet to Catch Up With Its Share Price Dec 22
Returns On Capital Are Showing Encouraging Signs At Alcon (VTX:ALC) Dec 04
Alcon Inc., Annual General Meeting, May 08, 2024 Dec 02
Alcon Inc. Revises Earnings Guidance for the Full Year 2023 Nov 17
Third quarter 2023 earnings: EPS exceeds analyst expectations Nov 15
Calculating The Fair Value Of Alcon Inc. (VTX:ALC) Nov 08
Alcon Inc. Showcases Cloud-Based Planning and World-Class Digital Technologies During AAO 2023 Oct 31
Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet Oct 18
Alcon Launches Total30 Multifocal Contact Lenses for Patients with Presbyopia Oct 11
Alcon (VTX:ALC) Might Have The Makings Of A Multi-Bagger Aug 25
Alcon Inc. Raises Earnings Guidance for the Full Year 2023 Aug 17
Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.30 in 2Q 2022) Aug 16
A Look At The Fair Value Of Alcon Inc. (VTX:ALC) Aug 10
Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet Jul 05
Head of Corporate Development notifies of intention to sell stock May 15
Investors Will Want Alcon's (VTX:ALC) Growth In ROCE To Persist May 12
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 10
Alcon Inc. Provides Earnings Guidance for the Year 2023 May 10
Alcon Announces Results from a New Study Presented at the American Society of Cataract and Refractive Surgery Annual Meeting May 07
Alcon Inc. Approves Dividend May 06
Upcoming dividend of CHF0.21 per share at 0.3% yield May 03
Does Alcon (VTX:ALC) Have A Healthy Balance Sheet? Apr 03
Full year 2022 earnings: EPS misses analyst expectations Feb 28
Now 21% undervalued Feb 24
Alcon Inc. Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices Feb 13
Alcon Launches New Total Toric Lenses for Astigmatic Patients Feb 03
Here's Why Alcon (VTX:ALC) Has Caught The Eye Of Investors Feb 03
Returns Are Gaining Momentum At Alcon (VTX:ALC) Jan 19 Alcon Inc., Annual General Meeting, May 05, 2023 Jan 10
Alcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for Astigmatism Jan 05
Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet Dec 18
Now 20% undervalued Nov 29
Alcon Inc. Updates Earnings Guidance for the Year 2022 Nov 17
Insufficient new directors Nov 16
Alcon Inc. Revises Revenue Guidance for 2022 Nov 16
Do Alcon's (VTX:ALC) Earnings Warrant Your Attention? Nov 02
Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022 Sep 30
Alcon's (VTX:ALC) Returns On Capital Are Heading Higher Sep 30
We Think Alcon (VTX:ALC) Can Stay On Top Of Its Debt Sep 11
With Alcon Inc. (VTX:ALC) It Looks Like You'll Get What You Pay For Aug 26
Alcon Inc. (SWX:ALC) entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) for approximately $770 million. Aug 24
Consensus forecasts updated Aug 16
Second quarter 2022 earnings: EPS exceeds analyst expectations Aug 10 Alcon Inc. Revises Revenue Guidance for 2022
These 4 Measures Indicate That Alcon (VTX:ALC) Is Using Debt Reasonably Well Jun 10
Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million. May 23
Alcon (VTX:ALC) Is Experiencing Growth In Returns On Capital May 20
Alcon Inc. Reaffirms Earnings Guidance for the Fiscal 2022 May 12
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 11 Alcon Inc. Declares Dividend for 2021
Insufficient new directors Apr 27
Alcon Announces Key Data to Be Presented at This Year’s American Society of Cataract and Refractive Surgery Meeting on its SMART Solutions for Cataract Surgery Apr 24
Alcon Inc. Announces Launch of Clareon Portfolio in the U.S Mar 08
Consensus EPS estimates increase by 12% Feb 24
Full year 2021 earnings: EPS exceeds analyst expectations Feb 16 Alcon Inc. Proposes Dividend
There's Been No Shortage Of Growth Recently For Alcon's (VTX:ALC) Returns On Capital Feb 13 Alcon Inc. Announces Launch of Systane Complete Preservative-Free Lubricant Eye Drops in Europe
Gewinn- und Umsatzwachstumsprognosen SWX:ALC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions) Datum Umsatz Gewinne Freier Cashflow Bargeld aus operativen Tätigkeiten Durchschn. Anz. Analysten 12/31/2026 11,300 1,457 1,766 2,550 17 12/31/2025 10,606 1,154 1,510 2,306 20 12/31/2024 9,895 923 1,274 2,022 14 9/30/2024 9,761 1,161 1,217 2,069 N/A 6/30/2024 9,636 1,102 1,086 1,849 N/A 3/31/2024 9,562 1,048 777 1,644 N/A 12/31/2023 9,455 974 535 1,388 N/A 9/30/2023 9,274 450 525 1,282 N/A 6/30/2023 9,085 362 317 1,157 N/A 3/31/2023 8,880 341 480 1,236 N/A 12/31/2022 8,717 335 -13 1,217 N/A 9/30/2022 8,695 571 -61 1,259 N/A 6/30/2022 8,657 457 -17 1,273 N/A 3/31/2022 8,550 460 -406 1,255 N/A 12/31/2021 8,291 376 165 1,345 N/A 9/30/2021 8,082 332 322 1,397 N/A 6/30/2021 7,818 183 307 1,307 N/A 3/31/2021 6,922 -390 364 949 N/A 12/31/2020 6,833 -531 256 823 N/A 9/30/2020 6,806 -717 132 730 N/A 6/30/2020 6,836 -636 62 677 N/A 3/31/2020 7,525 -604 275 920 N/A 12/31/2019 7,508 -656 244 920 N/A 9/30/2019 7,386 -638 134 800 N/A 6/30/2019 7,280 -779 178 886 N/A 3/31/2019 7,177 -362 178 893 N/A 12/31/2018 7,153 -227 428 1,140 N/A 9/30/2018 7,123 175 697 1,375 N/A 12/31/2017 6,792 256 N/A 1,218 N/A 12/31/2016 6,596 -170 N/A 1,245 N/A 12/31/2015 6,776 308 N/A 1,370 N/A
Mehr anzeigen
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ALCDas prognostizierte Gewinnwachstum (9.7% pro Jahr) liegt über der Sparquote (0.3%).
Ertrag vs. Markt: ALCDie Erträge des Unternehmens (9.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Swiss (11.2% pro Jahr).
Hohe Wachstumserträge: ALCDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich .
Einnahmen vs. Markt: ALCDie Einnahmen des Unternehmens (6.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swiss (4.1% pro Jahr).
Hohe Wachstumseinnahmen: ALCDie Einnahmen des Unternehmens (6.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ALCDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (8.5%).
Wachstumsunternehmen entdecken Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
